Introduction: The attention of scientists from many countries is focused on hormonal substances - adipokines at the present time. Lowering the level of the hormone adiponectin plays a central role in the development of obesity and cardiovascular disease in humans. The aim of the work is to determine the effect of complex therapy of thiotriazolin and L-lysine escinate on adipocyte secretion indices in patients with non-alcoholic fatty liver disease (NAFLD) with overweight and obesity.
Material and methods: 135 patients with overweight and obesity were examined, 46 of which were overweight (BMI-25-29.9 kg / m2), 34 were obesity grade I (BMI-30-34.9 kg / m2), 20 - Obesity II degree (BMI-35-39.9 kg / m2). 35 patients had normal body mass (BMI 18-24.9 kg / m2). We also examined 20 practically healthy persons. The age of the examinees varied, the median age was 55 years (intercourt scale Q1-Q3 from 40 to 61 years). The verification of the diagnosis of NAFLD was conducted in accordance with the recommendations of the Unified Clinical Protocol.
Results: The additional use of thiotriazolin and L-lysine escinate significantly influenced the adiponectin concentration level. Compared with the period before treatment, the adiponectin level increased in patients with overweight and obesity in 1,6 times (p <0.05). Compared to baseline, the adiponectin content in patients with NAFLD increased by 24.6-27.6% (p <0.05). Also, the level of leptin decreases significantly in patients with overweight and obesity (p <0.05).
Conclusions: Integrated therapy with thiotriazolin and L-lysine escinate is an effective way to normalize the level of adipokines in patients with NAFLD with overweight and obesity.
Keywords: nonalcoholic fatty liver disease; treatment; adipokines; insulin resistance.